VERONA

Principal Investigator/s:
Dr Dermot Linden

Name of the Study:
VERONA

Why is this Study important?
This Phase II study (RPL554-NCFB-220) is the first investigating the efficacy, safety, and pharmacokinetics of ensifentrine 3 mg twice daily in subjects with non-cystic fibrosis bronchiectasis.

What is the Research question/aim?
To evaluate the effects of twice-daily nebulised ensifentrine (3 mg) compared to placebo on pulmonary exacerbations.

What the Study involves:
Subjects randomised 1:1 to ensifentrine 3 mg BID or placebo BID for 24 weeks, continuing until 120 subjects experience ≥ 1 exacerbation.

Maximum = 3 years. All participants continue standard care therapy.

Who can take part in the Study?
Patients aged 18–85 with confirmed bronchiectasis. Target 4–5 participants.

Contact Information:
Áine Redfern-Walsh – Senior Clinical Research Nurse
aine.redfernwalsh@belfasttrust.hscni.net 028 9504 0342